FDA Gives Green Light to New Shingles Vaccine Syringe in USA -

Read Time:50 Second

The U.S. Food and Drug Administration (FDA) has approved a new prefilled syringe form of the Shingrix vaccine to prevent shingles in the United States. Shingles, also known as herpes zoster, is a painful skin rash caused by the reactivation of the chickenpox virus.

Shingrix is already a widely used vaccine that requires two doses to offer strong protection. This new prefilled syringe form aims to make vaccination easier and more convenient for both healthcare providers and patients.

Advertisements

Reduced preparation time
Ensured correct dosing
Enhanced convenience during administration

This approval marks a significant step in enhancing the effectiveness of shingles prevention efforts across the country. The vaccine continues to be recommended for adults aged 50 and older, who are at higher risk of developing shingles and its complications.

The FDA’s decision followed a thorough review of data showing the safety and effectiveness of the prefilled syringe version. Stay tuned for Questiqa USA for more latest updates.